Back to top

The MTN-039 Phase I study of a fast-dissolving rectal insert for HIV prevention has completed follow-up. The first ever study of the tenofovir and elvitegravir insert used rectally, MTN-039 enrolled 23 participants at two sites in the U.S.  It was designed to evaluate the safety and acceptability of the insert as well as the degree that each drug concentrates in rectal tissue.